tiprankstipranks
Trending News
More News >
Precigen (PGEN)
NASDAQ:PGEN

Precigen (PGEN) AI Stock Analysis

Compare
996 Followers

Top Page

PG

Precigen

(NASDAQ:PGEN)

Rating:51Neutral
Price Target:
$1.50
▼(-6.83%Downside)
Precigen's overall stock score is primarily impacted by its poor financial performance, which is a significant concern. However, technical analysis shows some positive momentum, and recent corporate events provide a boost to operational flexibility and shareholder value. The valuation remains a risk due to ongoing losses and lack of dividend yield.
Positive Factors
Manufacturing Capacity
Precigen has increased the manufacturing capacity at its GMP facilities to produce the drug for a successful commercial campaign upon approval.
Partnership Opportunities
UltraCAR-T platform and other assets represent partnership opportunities that have potential to generate non-dilutive funding.
Regulatory Approval
The FDA has granted the PRGN-2012 BLA priority review and established a PDUFA date, while indicating that it does not anticipate convening an AdComm to discuss the application.
Negative Factors
Commercial Adoption Challenges
Commercial adoption if approved will take time, with only one site at the NIH experienced in administering the treatment, and critical factors like cold chain storage and cost-related barriers to consider.
Financial Performance
For FY24, Precigen reported total revenue of $3.9M and a net loss of $0.47 per share, compared to the consensus estimated revenue of $4.1M and a net loss of 0.46 per share.
Regulatory Risk
There is regulatory risk with the current form of clinical data being single-arm and single investigator, and the ongoing confirmatory trial also being a single-arm study.

Precigen (PGEN) vs. SPDR S&P 500 ETF (SPY)

Precigen Business Overview & Revenue Model

Company DescriptionPrecigen, Inc. is a biotechnology company focused on the development of innovative gene and cell therapies. Operating primarily within the healthcare and life sciences sectors, Precigen aims to advance the next generation of gene and cell therapies to address unmet medical needs in areas such as oncology, autoimmune disorders, and infectious diseases. The company leverages its proprietary UltraCAR-T, ActoBiotics, and AdenoVerse platforms to create targeted and effective treatments.
How the Company Makes MoneyPrecigen generates revenue through a combination of strategic partnerships, collaborations, and licensing agreements. The company partners with other biotechnology and pharmaceutical companies to co-develop and commercialize its therapeutic candidates, receiving milestone payments and royalties as these products advance through clinical development and reach the market. Additionally, Precigen licenses its proprietary technology platforms to third parties, generating licensing fees and other related revenues. The company's earnings are also supported by government grants and research funding, which contribute to the advancement of its research and development initiatives.

Precigen Earnings Call Summary

Earnings Call Date:May 14, 2025
(Q4-2024)
|
% Change Since: 25.78%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong positive outlook, with significant progress in regulatory approval, commercial readiness, and promising clinical data for multiple programs. Despite an increased net loss and pending confirmatory trials, the positive developments and strategic readiness for PRGN-2012's launch overshadowed the lowlights.
Q4-2024 Updates
Positive Updates
PRGN-2012 FDA Priority Review
PRGN-2012 received FDA priority review with a PDUFA date set for August 27, 2025, indicating a strong regulatory progress and potential market entry.
Significant Efficacy in PRGN-2012 Trials
PRGN-2012 demonstrated a 51% complete response rate, with responders remaining surgery-free for up to three years, showcasing significant efficacy and durability.
Manufacturing Readiness for PRGN-2012
The company has upgraded its GMP facility and completed process validations, ensuring readiness for the commercial launch of PRGN-2012.
Expansion of Commercial Team
Precigen completed the build-out of its commercial leadership team and partnered with EVERSANA to implement the US launch, indicating robust preparations for commercialization.
Increased Market Opportunity
Updated analysis suggests there are up to 27,000 adult RRP patients in the US, indicating a larger market opportunity than previously estimated.
Successful Fundraising
Precigen raised $79 million through a preferred stock issuance, strengthening its balance sheet and extending its financial runway into 2026.
Promising Developments in PRGN-2009 and UltraCAR-T
Phase 1 data for PRGN-2009 showed 30% objective responses in refractory patients, and UltraCAR-T platform developments indicate potential first-in-class treatments for AML and autoimmune diseases.
Negative Updates
Increased Net Loss for 2024
The company reported a net loss of $126.2 million, an increase from $95.9 million in 2023, indicating rising expenses as the company prepares for commercialization.
Pending Confirmatory Trial Completion
The confirmatory trial for PRGN-2012 is still ongoing and is not expected to be completed by the PDUFA date, which could affect the timeline for final approval.
Company Guidance
During Precigen's Full Year 2024 Financial Results and Business Update Call, the company provided comprehensive guidance on various metrics surrounding their lead asset, PRGN-2012 for recurrent respiratory papillomatosis (RRP). The program has shown a 51% complete response rate in clinical trials, with a median durability of response at 24 months and all Phase 1 complete responders remaining surgery-free for three years. The FDA accepted their Biologics License Application (BLA) with a priority review and a PDUFA date set for August 27, 2025, without plans for an advisory committee meeting. Precigen reported a net loss of $126.2 million for 2024, compared to $95.9 million in 2023, and ended the year with $97.9 million in cash, cash equivalents, and investments. The company plans to target approximately 500 otolaryngologists in the U.S. with a sales force of 15-20 representatives in partnership with EVERSANA, anticipating commercial revenues beginning in the second half of 2025. The potential patient population in the U.S. is estimated at 27,000 adults, indicating a significant unmet need.

Precigen Financial Statement Overview

Summary
Precigen's financial performance is severely challenged by declining revenues, negative profit margins, and high liabilities. Negative equity and reliance on external financing further underscore significant financial instability.
Income Statement
30
Negative
Precigen's income statement reflects significant challenges with declining revenues and negative profit margins. The gross profit margin is negative at -2.17% TTM, indicating costs exceed sales. The net profit margin is also severely negative at -3728.79% TTM, showing substantial losses. Revenue has decreased drastically over recent periods, with a TTM revenue growth rate of -32.56%. EBIT and EBITDA margins are also negative, highlighting ongoing operational inefficiencies.
Balance Sheet
25
Negative
The balance sheet shows financial instability, with negative stockholders' equity of -$14.06 million TTM, indicating liabilities exceed assets. The debt-to-equity ratio isn't applicable due to negative equity, but the presence of high total liabilities of $142.85 million suggests significant leverage. The equity ratio is negative, further emphasizing the weak financial position. Return on equity is not applicable due to negative equity.
Cash Flow
40
Negative
Cash flow analysis shows continuous negative free cash flow, with a slight improvement in operating cash flow. Free cash flow growth rate is slightly positive at 1.95% TTM, but remains negative overall at -$75.26 million. The operating cash flow to net income ratio is 0.45 TTM, reflecting some operational cash generation despite losses. However, the company is heavily reliant on financing activities for cash inflow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.20M3.92M6.22M26.91M103.87M103.18M
Gross Profit-91.00K-342.00K106.00K20.57M45.49M47.66M
EBITDA-154.85M-123.50M-89.23M-66.00M-84.07M-70.41M
Net Income-156.65M-126.23M-95.90M-79.78M-96.77M-103.77M
Balance Sheet
Total Assets128.79M145.27M151.04M215.98M359.86M314.59M
Cash, Cash Equivalents and Short-Term Investments80.24M97.91M62.85M55.95M115.16M100.12M
Total Debt5.42M5.50M7.10M51.42M194.20M182.28M
Total Liabilities142.85M106.75M32.55M89.72M252.51M247.41M
Stockholders Equity-14.06M38.51M118.50M126.26M107.35M67.17M
Cash Flow
Free Cash Flow-75.26M-76.76M-68.47M-69.97M-63.02M-84.55M
Operating Cash Flow-70.41M-68.17M-66.93M-65.05M-55.77M-77.02M
Investing Cash Flow-51.22M-20.71M-3.09M226.42M-74.54M27.78M
Financing Cash Flow109.90M110.58M29.59M-155.29M121.19M32.70M

Precigen Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.61
Price Trends
50DMA
1.44
Positive
100DMA
1.56
Positive
200DMA
1.26
Positive
Market Momentum
MACD
0.02
Negative
RSI
62.56
Neutral
STOCH
44.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Positive. The current price of 1.61 is above the 20-day moving average (MA) of 1.47, above the 50-day MA of 1.44, and above the 200-day MA of 1.26, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.56 is Neutral, neither overbought nor oversold. The STOCH value of 44.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGEN.

Precigen Risk Analysis

Precigen disclosed 61 risk factors in its most recent earnings report. Precigen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Precigen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$520.77M-216.14%203.23%-80.71%
54
Neutral
$603.49M-45.46%-78.26%15.41%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
51
Neutral
$428.01M-278.55%-22.76%-46.69%
41
Neutral
$516.89M-27.04%6.72%
40
Neutral
$504.70M-37.07%26.24%
33
Underperform
$658.62M-71.44%19.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PGEN
Precigen
1.61
0.19
13.38%
MGTX
Meiragtx Holdings
6.92
2.90
72.14%
RLAY
Relay Therapeutics
3.60
-2.76
-43.40%
SANA
Sana Biotechnology
2.92
-2.17
-42.63%
MNMD
Mind Medicine
7.08
0.00
0.00%
TYRA
Tyra Bioscience
10.05
-7.05
-41.23%

Precigen Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
Precigen Announces Key Approvals at Annual Meeting
Positive
Jun 30, 2025

At the Annual Meeting of Stockholders on June 26, 2025, Precigen, Inc. announced several key approvals, including an amendment to increase the shares available under its 2023 Omnibus Incentive Plan by 11.5 million. Additionally, stockholders approved increasing the company’s authorized shares of common stock by 300 million and ratified Deloitte & Touche LLP as the independent accounting firm for 2025. These decisions are expected to impact Precigen’s operational flexibility and shareholder value positively.

The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025